Takeda unveils three new discovery and development collaborations in immuno-oncology
January 4, 2019Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma
Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …
BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
January 4, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, acquisition, pharma
Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of …
Children should be given flu vaccine to protect older people
December 21, 2018Medical Communications epidemiology, flu, health, public health, vaccines
Parents are being urged to give their children the flu vaccine in order to protect ‘older people’ from the potentially …
Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus
December 21, 2018Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology
California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …
Top Ten most popular articles on Pharmafile.com of 2018!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Business, biosimilars, brexit, pharma, top 10
Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical …
J&J’s Baby powder tested in India and Bangladesh
December 21, 2018Medical Communications Bangladesh, Cancer, India, J&J, JJ, asbestos
Bangladeshi authorities will collect and test samples of Johnson & Johnson’s baby powders for traces of cancer causing asbestos, after …
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million
December 20, 2018Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …
Novartis Oncology CEO steps down after 11 months
December 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Liz Barret, the CEO of Swiss firm Novartis Oncology has said that she is standing down after being in the …
KCL researchers find link between overactive immune system and Chronic Fatigue Syndrome/ ME
December 20, 2018Research and Development CFS, KCL, King's College London, Kings College London, ME
Chronic fatigue syndrome (CFS) or Myalgic encephalomyelitis (ME) may be caused by an overactive immune system, according to researchers at …
Medics in Vanuatu transport vaccines via drone
December 20, 2018Business Services, Medical Communications Transport, Vanuata, drone, supply chain, vaccines
Medics in the remote archipelago of Vanuatu have begun to deliver vaccines using a commercial drone. The logistical success marks …
Gilead and Scholar Rock collaborate on fibrosis in deal worth more than $80m
December 20, 2018Business Services, Research and Development Califonia, Gilead, Scholar Rock, USA, fibrosis
California-based antiviral drugs specialist Gilead Sciences has entered into a strategic partnership with Cambridge, Massachusetts-based biotech Scholar Rock as part …
AstraZeneca scores hat trick in ovarian cancer and anaemia clinical trials
December 20, 2018Research and Development AstraZeneca, anaemia, oncology, ovarian cancer, pharma
Anglo-Swedish multinational AstraZeneca has revealed that its ovarian cancer drug (Lynparza) and anaemia treatment (Roxadustat) have met their goals in …
Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn
December 19, 2018Business Services BMS, Japan, M&A, MA, Taisho, deal
Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business. With more than a …
NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer
December 19, 2018Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma
UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …
China becomes first country to approve roxadustat in chronic kidney disease
December 19, 2018Research and Development, Sales and Marketing AstraZeneca, China, chronic kidney disease, pharma
AstraZeneca has announced that its partner Fibrogen has secured the first national approval for its hypoxia-inducible factor prolyl hydroxylase inhibitor …
Indian authorities seize J&J Baby Powder in response to Reuters report
December 19, 2018Research and Development Cancer, India, J&J, JJ, asbestos, baby powder, regulation
Indian authorities have seized samples of Johnson & Johnson’s Baby Powder from a factory in Baddi in Northern India, after …
GSK and Pfizer combine healthcare units in multibillion dollar deal
December 19, 2018Research and Development GSK, OTC, Pfizer, healthcare, merger
American multinational Pfizer and British firm GlaxoSmithKline are set to combine their consumer healthcare units in a venture worth billions. …
Novartis inks deal with Canadian cannabis firm Tilray
December 18, 2018Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis
Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …
Pharma in 2018: Looking back, looking forward
December 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma
2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
